NCT01199068 2021-05-13
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
Phase 1 Completed
Clinical Trials
9 trialsNCT00986440 2020-11-05
Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy
Daiichi Sankyo
Phase 2 Terminated
NCT00408434 2020-10-19
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
Daiichi Sankyo
Phase 1 Completed
NCT00881569 2020-09-28
Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017
Daiichi Sankyo
Phase 1 Completed
NCT00603941 2020-09-16
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Daiichi Sankyo
Phase 1/2 Terminated
NCT01199055 2020-07-07
CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
Phase 1 Completed
NCT01101334 2020-06-16
Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 2 Completed
NCT00806286 2020-05-13
Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 2 Completed
NCT00967616 2020-05-04
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Daiichi Sankyo
Phase 2 Completed